James Baillieu (Bird & Bird)

article

Boom times for pharma M&A

18 February 2021 | By James Baillieu (Bird & Bird)

Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…

article

Exploring and deploying blockchain solutions in the life sciences and healthcare sectors

28 August 2020 | By James Baillieu (Bird & Bird), Jonathan Emmanuel (Bird & Bird)

Blockchain is perhaps best known as the technology on which Bitcoin and other cryptocurrencies are built. Notwithstanding that adoption in the life sciences and healthcare sectors is still in its relative infancy, companies and other organisations in these sectors are increasingly exploring and deploying blockchain solutions. Here, legal experts James…